HealthEquity (HQY) Q4 2026 Earnings Transcript

HealthEquity reported Q4 revenue of $334.6M (+7% YoY) with adjusted EBITDA of $132.9M (+23%) and an expanded adjusted EBITDA margin of 40% (+500 bps); GAAP net income was $49.7M (+93%). Total HSAs reached 17.8M and HSA assets surpassed $36B (+14%), while service/custodial/interchange trends were healthy and fraud costs fell to a 0.1 bps run rate for the quarter. Management raised FY2027 guidance to revenue $1.405–$1.415B, GAAP net income $239–$246M, non‑GAAP net income $392–$400M and adjusted EBITDA $618–$628M (shares ~86M); capital returns included >$300M repurchased in FY2026 with $178M remaining. Strategic positives: ~ $2.4B Treasury forward hedges at a 3.92% blended lock, early traction for a new HSA-linked marketplace, AI-driven service automation, and a regulatory tailwind from ACA bronze-plan HSA eligibility (~10% market expansion).

Analysis

HealthEquity’s last-mile moves (rate hedging, enhanced-rate placements, app-driven engagement and a marketplace) are best read as a deliberate shift from volatile custodial spreads toward recurring, higher‑quality margin. Converting variable short‑rate exposure into a hedged, multi‑year yield profile reduces quarter-to-quarter earnings jitter and gives management optionality to accelerate buybacks or tuck‑ins; the offset is increased basis and counterparty risk on the derivative book that will show through mark‑to‑market swings if the curve reverts.

The marketplace + ACA retail channel is a nonlinear growth vector: bringing previously off‑platform spend into the ecosystem compounds lifetime value through higher contribution cadence and more frequent wallet touchpoints. Early monetization may be modest, but the strategic lever is behavioral — getting members to treat HSA balances as a routine payment instrument drives both interchange volume and replenishment behavior, which can push ARPU materialy over 12–36 months and create a recurring take‑rate stream.

AI and fraud control are margin multipliers but execution dependent. Automation can compress service cost per account substantially only if false‑positive rates stay low and integration with legacy client onboarding is seamless; missteps (member friction, regulatory scrutiny, or a material data incident) would reverse margin gains quickly. Key short‑to‑medium catalysts to watch are enrollment cycles, Treasury curve moves, marketplace cohort retention after 6–12 months, and derivative MTM disclosures.

Key Decisions for Investors

• Long HQY equity with downside protection (buy HQY stock and buy a 9–12 month slightly OTM protective put, financed by selling a 9–12 month OTM covered call). Trade rationale: capture continued margin expansion and optionality from marketplace/ACA rollouts; target +30% upside over 12 months, define max loss as cost of protective put (~<8–12% of position value).
• Paired trade — long HQY / short regional-bank exposure (e.g., sell a small WFC position or short a regional bank ETF) for 6–12 months. Rationale: disintermediation of low‑cost deposits and higher interchange economics favor platform owner vs deposit‑rich banks. Risk/reward: asymmetric — 20–30% upside if thesis plays out; tail risk if rates fall and deposit dynamics normalize.
• Buy Visa (V) 12–18 month calls or add modest long exposure to card network. Rationale: accelerating HSA card volume and higher take‑rates increase merchant fees/interchange sensitivity; expect steady, low‑volatility upside. Position size: tactical (3–5% portfolio), target 15–25% return.
• Hedge tail risk: buy 12–18 month OTM put on HQY (small size, 1–2% portfolio). Rationale: protects against regulation reversal, major data breach, or a sharp curve move that creates adverse derivative MTM. Cost is insurance against event risk.